GlassScriptPhysician profile
Ken Philip Ehrhardt
NPI 1033571914
$22,203.48
in general payments reported to CMS, 2019-2025
39 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $984 · 2021: $1,393 · 2022: $1,325 · 2023: $841 · 2024: $936 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $4,283 · Travel and Lodging: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,610.00 |
| Food and Beverage | $4,283.19 |
| Travel and Lodging | $1,380.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $13,670.39 | 2025 | |
| Boston Scientific Corporation | $1,878.27 | 2019-2022 | |
| Spinal Simplicity, LLC | $1,422.54 | 2022-2025 | Ha Minuteman G3-R |
| Globus Medical, INC. | $1,119.34 | 2025 | Senza, Vyrsa V1 |
| Nevro Corp. | $653.60 | 2020-2024 | Senza |
| Collegium Pharmaceutical, INC. | $628.95 | 2021-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $432.98 | 2025 | Prospera |
| Medtronic, INC. | $206.55 | 2021-2024 | Synchromedii |
| Lilly USA, LLC | $183.68 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Virtus Pharmaceuticals LLC | $160.29 | 2023-2025 | Levorphanol Tartrate |
| Abbvie INC. | $155.99 | 2022-2025 | |
| Spr Therapeutics, INC | $155.53 | 2021-2025 | Sprint Pns System |
| Forte Bio-Pharma LLC | $150.36 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Jazz Pharmaceuticals INC. | $147.89 | 2023-2025 | |
| Saluda Medical Americas, INC. | $143.83 | 2023 | Evoke Scs |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Ehrhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.